Penetration of doripenem into prostatic tissue following intravenous administration in prostatectomy patients

International Journal of Antimicrobial Agents

Volumn 35, Issue 5, 2010, Pages 504-506

  Yamada, Yoshiaki ^a   Ikawa, Kazuro ^b   Nakamura, Kogenta ^a   Mitsui, Kenji ^c   Narushima, Masahiro ^d   Hibi, Hatsuki ^e   Ikeda, Kayo ^b   Morikawa, Norifumi ^b   Honda, Nobuaki ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c Tokoname Municipal Hospital   (Japan)

^d Meitetsu Hospital   (Japan)

^e Kyoritsu General Hospital   (Japan)

Author keywords

Bacterial prostatitis; Carbapenem; Pharmacokinetics

Indexed keywords

DORIPENEM;

AGED; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG PENETRATION; DRUG TISSUE LEVEL; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATITIS; TRANSURETHRAL RESECTION; URINARY TRACT INFECTION;

AGED; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CHROMATOGRAPHY; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSTATE; PROSTATECTOMY; SERUM;

EID: 77949653159     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.01.008     Document Type: Article

References (14)

1. Keam S.J. Doripenem: a review of its use in the treatment of bacterial infections. Drugs 2008, 68:2021-2057.
2. Shionogi & Co. Ltd. Finibax® prescribing information (interview form), February 2008 version. Osaka, Japan: Shionogi & Co. Ltd.
3. Zhanel G.G., Wiebe R., Dilay L., Thomson K., Rubinstein E., Hoban D.J., et al. Comparative review of the carbapenems. Drugs 2007, 67:1027-1052.
4. Greer N.D. Doripenem (Doribax): the newest addition to the carbapenems. Proc (Bayl Univ Med Cent) 2008, 21:337-341.
5. Matthews S.J., Lancaster J.W. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic. Clin Ther 2009, 31:42-63.
6. Ikeda K., Ikawa K., Morikawa N., Kameda K., Urakawa N., Ohge H., et al. Quantification of doripenem in human plasma and peritoneal fluid by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2008, 867:20-25.
7. Hori T., Nakano M., Kimura Y., Murakami K. Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. In Vivo 2006, 20:91-96.
8. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T. A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobiodyn 1981, 4:879-885.
9. Drusano G.L., Preston S.L., Van Guilder M., North D., Gombert M., Oefelein M., et al. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother 2000, 44:2046-2051.
10. Charalabopoulos K., Karachalios G., Baltogiannis D., Charalabopoulos A., Giannakopoulos X., Sofikitis N. Penetration of antimicrobial agents into the prostate. Chemotherapy 2003, 49:269-279.
11. Naber K.G., Adam D., Bauernfeind A., Hönig E. Imipenem/cilastatin: in vitro activity, concentrations in plasma and prostatic adenoma and therapeutic results in patients with complicated urinary tract infections. Infection 1986, 14(Suppl. 2):S122-S129.
12. Naber K.G., Sörgel F. Antibiotic therapy-rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia 2003, 35:331-335.
13. Wagenlehner F.M., Weidner W., Sörgel F., Naber K.G. The role of antibiotics in chronic bacterial prostatitis. Int J Antimicrob Agents 2005, 26:1-7.
14. Mouton J.W., Theuretzbacher U., Craig W.A., Tulkens P.M., Derendorf H., Cars O. Tissue concentrations: do we ever learn?. J Antimicrob Chemother 2008, 61:235-237.